Radiation Therapy Regimens in Treating Patients With Limited-Stage Small Cell Lung Cancer Receiving Cisplatin and Etoposide
Status: | Recruiting |
---|---|
Conditions: | Lung Cancer, Cancer |
Therapuetic Areas: | Oncology |
Healthy: | No |
Age Range: | 18 - Any |
Updated: | 3/7/2019 |
Start Date: | March 2008 |
Contact: | Jeffrey A. Bogart, MD |
Phone: | 315 464-5276 |
Phase III Comparison of Thoracic Radiotherapy Regimens in Patients With Limited Small Cell Lung Cancer Also Receiving Cisplatin and Etoposide
Radiation therapy uses high-energy x-rays to kill tumor cells. Drugs used in chemotherapy,
such as etoposide, carboplatin and cisplatin, work in different ways to stop the growth of
tumor cells, either by killing the cells or by stopping them from dividing. It is not yet
known which radiation therapy regimen is more effective when given together with chemotherapy
in treating patients with limited-stage small cell lung cancer. This randomized phase III
trial is comparing different chest radiation therapy regimens to see how well they work in
treating patients with limited-stage small cell lung cancer.
such as etoposide, carboplatin and cisplatin, work in different ways to stop the growth of
tumor cells, either by killing the cells or by stopping them from dividing. It is not yet
known which radiation therapy regimen is more effective when given together with chemotherapy
in treating patients with limited-stage small cell lung cancer. This randomized phase III
trial is comparing different chest radiation therapy regimens to see how well they work in
treating patients with limited-stage small cell lung cancer.
OUTLINE: This is a 2-part, multicenter, randomized study. Patients are stratified according
to gender, weight loss 6 months prior to study entry (≤ 5% of body weight vs > 5% of body
weight), ECOG performance status (0 vs 1 vs 2), radiotherapy technique (intensity-modulated
radiotherapy vs 3-dimensional conformal radiotherapy), radiotherapy start time (at first
cycle of protocol chemotherapy, after one cycle of prior non-protocol chemotherapy vs at
first cycle of protocol chemotherapy, without prior non-protocol chemotherapy vs at second
cycle of protocol chemotherapy, without prior non-protocol chemotherapy) and chemotherapy
backbone: carboplatin vs cisplatin.
OBJECTIVES:
Primary Objective
To determine whether administering high dose thoracic radiotherapy, 70 Gy (2 Gy once-daily
over 7 weeks) or 61.2 Gy (1.8 Gy once-daily for 16 days followed by 1.8 Gy twice-daily for 9
days), will improve median and 2-year survival compared with 45 Gy (1.5 Gy twice-daily over 3
weeks) in patients with limited stage small cell lung cancer.
Secondary Objectives
1. To compare treatment related toxic effects of thoracic radiotherapy regimens in patients
with limited stage small cell lung cancer
2. To compare response rates, failure-free survival and toxicity of thoracic radiotherapy
regimens in patients with limited stage small cell lung cancer
3. To compare rates of local relapse, distant metastases and brain metastases with these
regimens
4. To compare patients' quality of life between these treatment regimens in terms of their
physical symptoms, physical functioning and psychological state
5. To describe the patterns of use of thoracic intensity modulated radiation therapy (IMRT)
in patients with limited stage small cell lung cancer
6. To examine blood-based biomarkers of response and resistance to cisplatin (or
carboplatin) and etoposide
7. To evaluate the correspondence between increases in plasma ProGRP concentrations and
disease progression/recurrence
8. To evaluate the potential for plasma ProGRP concentrations at baseline, after each cycle
of chemotherapy and at first evaluation following completion of chemotherapy to predict
PFS and OS
9. To evaluate the correspondence between longitudinal decreases in plasma ProGRP
concentrations and clinical response
Part 1: Patients are randomized to 1 of 3 treatment arms.
Arm I: Patients undergo standard-dose (45 Gy given in 30 treatments) thoracic radiotherapy
twice daily, 5 days a week, for 3 weeks. Patients also receive cisplatin IV on day 1 or
carboplatin IV and etoposide IV on days 1, 2, and 3.
Arm II: Patients undergo higher-dose (70 Gy given in 35 treatments) thoracic radiotherapy
once daily, 5 days a week, for 7 weeks. Patients also receive cisplatin or carboplatin and
etoposide as in arm I.
Arm III: (discontinued as of 03/10/13) Patients undergo mid-dose (61.2 Gy given in 34
treatments) thoracic radiotherapy once daily, 5 days a week, during the initial 16 days
(approximately 3 weeks) of treatment and then twice daily, 5 days a week, for the final 9
days (approximately 2 weeks) of treatment. Patients also receive cisplatin and etoposide.
In all arms, treatment with cisplatin and etoposide repeats every 21 days for 4 courses in
the absence of disease progression or unacceptable toxicity.
Part 2: An interim analysis was conducted after accrual of 30 patients per arm and one
experimental arm based upon a comparison of treatment-related toxicity was selected. The most
toxic experimental arm was discontinued, and the trial continues comparing standard therapy
(arm I) to the selected experimental regimen (arm II) as described in part 1. Please see the
Arms section for more information regarding Part 2.
Prophylactic cranial irradiotherapy (PCI): Within 3-6 weeks after completion of chemotherapy,
PCI should be offered to all patients with a complete tumor response (CR) or near complete
response (nCR) with only residual chest abnormalities of indeterminate nature following
completion of combined modality therapy.
After completion of study treatment, patients are followed up at least every 3 months for 2
years, every 6 months for 3 years, and then annually for 5 years or until disease
progression. At disease progression, patients are followed up every 6 months.
to gender, weight loss 6 months prior to study entry (≤ 5% of body weight vs > 5% of body
weight), ECOG performance status (0 vs 1 vs 2), radiotherapy technique (intensity-modulated
radiotherapy vs 3-dimensional conformal radiotherapy), radiotherapy start time (at first
cycle of protocol chemotherapy, after one cycle of prior non-protocol chemotherapy vs at
first cycle of protocol chemotherapy, without prior non-protocol chemotherapy vs at second
cycle of protocol chemotherapy, without prior non-protocol chemotherapy) and chemotherapy
backbone: carboplatin vs cisplatin.
OBJECTIVES:
Primary Objective
To determine whether administering high dose thoracic radiotherapy, 70 Gy (2 Gy once-daily
over 7 weeks) or 61.2 Gy (1.8 Gy once-daily for 16 days followed by 1.8 Gy twice-daily for 9
days), will improve median and 2-year survival compared with 45 Gy (1.5 Gy twice-daily over 3
weeks) in patients with limited stage small cell lung cancer.
Secondary Objectives
1. To compare treatment related toxic effects of thoracic radiotherapy regimens in patients
with limited stage small cell lung cancer
2. To compare response rates, failure-free survival and toxicity of thoracic radiotherapy
regimens in patients with limited stage small cell lung cancer
3. To compare rates of local relapse, distant metastases and brain metastases with these
regimens
4. To compare patients' quality of life between these treatment regimens in terms of their
physical symptoms, physical functioning and psychological state
5. To describe the patterns of use of thoracic intensity modulated radiation therapy (IMRT)
in patients with limited stage small cell lung cancer
6. To examine blood-based biomarkers of response and resistance to cisplatin (or
carboplatin) and etoposide
7. To evaluate the correspondence between increases in plasma ProGRP concentrations and
disease progression/recurrence
8. To evaluate the potential for plasma ProGRP concentrations at baseline, after each cycle
of chemotherapy and at first evaluation following completion of chemotherapy to predict
PFS and OS
9. To evaluate the correspondence between longitudinal decreases in plasma ProGRP
concentrations and clinical response
Part 1: Patients are randomized to 1 of 3 treatment arms.
Arm I: Patients undergo standard-dose (45 Gy given in 30 treatments) thoracic radiotherapy
twice daily, 5 days a week, for 3 weeks. Patients also receive cisplatin IV on day 1 or
carboplatin IV and etoposide IV on days 1, 2, and 3.
Arm II: Patients undergo higher-dose (70 Gy given in 35 treatments) thoracic radiotherapy
once daily, 5 days a week, for 7 weeks. Patients also receive cisplatin or carboplatin and
etoposide as in arm I.
Arm III: (discontinued as of 03/10/13) Patients undergo mid-dose (61.2 Gy given in 34
treatments) thoracic radiotherapy once daily, 5 days a week, during the initial 16 days
(approximately 3 weeks) of treatment and then twice daily, 5 days a week, for the final 9
days (approximately 2 weeks) of treatment. Patients also receive cisplatin and etoposide.
In all arms, treatment with cisplatin and etoposide repeats every 21 days for 4 courses in
the absence of disease progression or unacceptable toxicity.
Part 2: An interim analysis was conducted after accrual of 30 patients per arm and one
experimental arm based upon a comparison of treatment-related toxicity was selected. The most
toxic experimental arm was discontinued, and the trial continues comparing standard therapy
(arm I) to the selected experimental regimen (arm II) as described in part 1. Please see the
Arms section for more information regarding Part 2.
Prophylactic cranial irradiotherapy (PCI): Within 3-6 weeks after completion of chemotherapy,
PCI should be offered to all patients with a complete tumor response (CR) or near complete
response (nCR) with only residual chest abnormalities of indeterminate nature following
completion of combined modality therapy.
After completion of study treatment, patients are followed up at least every 3 months for 2
years, every 6 months for 3 years, and then annually for 5 years or until disease
progression. At disease progression, patients are followed up every 6 months.
1. Documentation of Disease
1. Histologically or cytologically documented small cell lung cancer (SCLC)
2. Limited-stage disease patients with disease restricted to one hemithorax with
regional lymph node metastases, including ipsilateral hilar, ipsilateral and
contralateral mediastinal, and ipsilateral supraclavicular lymph nodes
- Patients with disease involvement of the contralateral hilar or
supraclavicular lymph nodes are not eligible
- Patients with pleural effusions that are visible on plain chest radiographs,
whether cytologically positive or not are not eligible unless they have a
negative thoracentesis
- Patients with cytologically positive pleural or pericardial fluid,
regardless of the appearance on plain x-ray are not eligible
2. Measurable disease - Patients must have measurable disease, which includes lesions
that can be accurately measured in at least one dimension (longest diameter to be
recorded) as ≥ 2 cm with conventional techniques OR ≥ 1 cm by spiral CT scan
3. Prior Treatment
1. Patients may have received one and only one cycle of chemotherapy prior to
enrolling on CALGB 30610, which must have included carboplatin or cisplatin and
etoposide.
2. If a patient has had one cycle of cisplatin or carboplatin/etoposide prior to
registration, the patient must have had all of it prior to registration tests as
outlined in the protocol and prior to starting their first cycle of chemotherapy.
3. Additionally, these patients also must have met all of the eligibility criteria
in the protocol prior to receiving the first cycle of chemotherapy.
4. Registration to CALGB 30610 must take place within 14-21 days after the start of
the non-protocol therapy.
5. Failing to do all of the above will make the patient NOT eligible for CALGB
30610.
6. No prior radiotherapy or chemotherapy (except for the chemotherapy described in
the bullet above) for SCLC
7. No prior mediastinal or thoracic radiotherapy
8. Patients with complete surgical resection of disease are not eligible
4. Age Requirement ≥ 18 years of age
5. ECOG Performance Status 0-2
6. Non-pregnant and non-nursing - No patients that are known to be pregnant or nursing
7. Required Initial Laboratory Values
1. Granulocytes ≥ 1,500/µl
2. Platelet count ≥ 100,000/µl
3. Total bilirubin ≤ 1.5 times upper limit of normal (ULN)
4. AST (SGOT) ≤ 2.0 times ULN
5. Serum creatinine ≤ 1.5 times ULN OR Calculated creatinine clearance ≥ 70 mL/min
We found this trial at
906
sites
Click here to add this to my saved trials
1201 Camino de Salud Northeast
Albuquerque, New Mexico 87131
Albuquerque, New Mexico 87131
(505) 272-4946
Principal Investigator: Vi K. Chiu
Phone: 505-925-0366
University of New Mexico Cancer Center It’s been 40 years since the New Mexico State...
Click here to add this to my saved trials
2545 Schoenersville Rd
Bethlehem, Pennsylvania 18017
Bethlehem, Pennsylvania 18017
(484) 884-2200
Principal Investigator: Samir Narayan
Phone: 734-712-3671
Lehigh Valley Hospital - Muhlenberg At Lehigh Valley Health Network, we continually go the extra...
Click here to add this to my saved trials
75 Francis street
Boston, Massachusetts 02115
Boston, Massachusetts 02115
(617) 732-5500
Principal Investigator: David E. Kozono
Phone: 773-702-9171
Brigham and Women's Hosp Boston’s Brigham and Women’s Hospital (BWH) is an international leader in...
Click here to add this to my saved trials
Tufts Medical Center Tufts Medical Center is an internationally-respected academic medical center – a teaching...
Click here to add this to my saved trials
Bremerton, Washington 98310
Principal Investigator: Richard L. Deming
Phone: 308-398-6518
Click here to add this to my saved trials
1 Hurley Plaza
Flint, Michigan 48503
Flint, Michigan 48503
(810) 262-9000
Principal Investigator: Samir Narayan
Phone: 734-712-3671
Hurley Medical Center From its founding in 1908, Hurley Medical Center has devoted itself to...
Click here to add this to my saved trials
4725 North Federal Highway
Fort Lauderdale, Florida 33308
Fort Lauderdale, Florida 33308
(954) 771-8000
Principal Investigator: Michael A. Schwartz
Phone: 954-267-7750
Holy Cross Hospital While spirituality plays an essential role in the way that we minister...
Click here to add this to my saved trials
301 University Blvd
Galveston, Texas 77555
Galveston, Texas 77555
(409) 772-1011
Principal Investigator: Todd A. Swanson
Phone: 409-772-1950
University of Texas Medical Branch Established in 1891 as the University of Texas Medical Department,...
Click here to add this to my saved trials
2500 N State St
Jackson, Mississippi 39216
Jackson, Mississippi 39216
(601) 984-1000
Principal Investigator: Louis V. Puneky
Phone: 601-815-6700
University of Mississippi Medical Center The University of Mississippi Medical Center, located in Jackson, is...
Click here to add this to my saved trials
Click here to add this to my saved trials
Bronson Methodist Hospital Our healthcare system serves patients and families throughout southwest Michigan and northern...
Click here to add this to my saved trials
200 North Park Street
Kalamazoo, Michigan 49007
Kalamazoo, Michigan 49007
(269) 382-2500
Principal Investigator: Kathleen J. Yost
Phone: 616-391-1230
West Michigan Cancer Center In 1994, Borgess Health Alliance and Bronson Healthcare Group opened the...
Click here to add this to my saved trials
1800 West Charleston Boulevard
Las Vegas, Nevada 89102
Las Vegas, Nevada 89102
(702) 383-2000
Principal Investigator: John A. Ellerton
Phone: 702-384-0013
University Medical Center of Southern Nevada University Medical Center is dedicated to providing the highest...
Click here to add this to my saved trials
529 West Markham Street
Little Rock, Arkansas 72205
Little Rock, Arkansas 72205
(501) 686-7000
Phone: 501-686-8511
University of Arkansas for Medical Sciences The University of Arkansas for Medical Sciences (UAMS) in...
Click here to add this to my saved trials
4805 Northeast Glisan Street
Portland, Oregon 97213
Portland, Oregon 97213
(503) 215-1111
Principal Investigator: Alison K. Conlin
Phone: 503-215-2614
Providence Portland Medical Center We strive to give those we serve exceptional, compassionate health care...
Click here to add this to my saved trials
60 Crittenden Blvd # 70
Rochester, New York 14642
Rochester, New York 14642
(585) 275-2121
Principal Investigator: Yuhchyau Chen
Phone: 585-275-5830
University of Rochester The University of Rochester is one of the country's top-tier research universities....
Click here to add this to my saved trials
4502 Medical Drive
San Antonio, Texas 78284
San Antonio, Texas 78284
(210) 567-7000
Phone: 210-567-4777
University of Texas Health Science Center at San Antonio The University of Texas Health Science...
Click here to add this to my saved trials
Seattle, Washington 98104
Principal Investigator: Alison K. Conlin
Phone: 206-215-3086
Click here to add this to my saved trials
Click here to add this to my saved trials
Aberdeen, Washington 98520
Principal Investigator: Alison K. Conlin
Phone: 360-412-8958
Click here to add this to my saved trials
1200 Old York Road
Abington, Pennsylvania 19001
Abington, Pennsylvania 19001
(215) 481–2000
Principal Investigator: Wayne H. Pinover
Phone: 215-481-2402
Abington Memorial Hospital Abington Memorial Hospital (AMH) is a 665-bed, regional referral center and teaching...
Click here to add this to my saved trials
Akron, Ohio 44304
Principal Investigator: Desiree E. Doncals
Phone: 330-375-6101
Click here to add this to my saved trials
Click here to add this to my saved trials
Allentown, Pennsylvania 18103
Principal Investigator: Samir Narayan
Phone: 734-712-3671
Click here to add this to my saved trials
Click here to add this to my saved trials
Amarillo, Texas 79106
Principal Investigator: Suhasini (Sue) Nadesan
Phone: 806-212-1985
Click here to add this to my saved trials
Anaconda, Montana 59711
Principal Investigator: Benjamin T. Marchello
Phone: 406-969-6060
Click here to add this to my saved trials
Anacortes, Washington 98221
Principal Investigator: Alison K. Conlin
Phone: 503-215-2614
Click here to add this to my saved trials
Anchorage, Alaska 99508
Principal Investigator: Alison K. Conlin
Phone: 907-212-6871
Click here to add this to my saved trials
Anchorage, Alaska 99508
Principal Investigator: Alison K. Conlin
Phone: 907-212-6871
Click here to add this to my saved trials
Anchorage, Alaska 99508
Principal Investigator: Alison K. Conlin
Phone: 907-212-6871
Click here to add this to my saved trials
Anchorage, Alaska 99508
Principal Investigator: Alison K. Conlin
Phone: 907-212-6871
Click here to add this to my saved trials
Click here to add this to my saved trials
Anchorage, Alaska 99508
Principal Investigator: Alison K. Conlin
Phone: 907-212-6871
Click here to add this to my saved trials
Anchorage, Alaska 99508
Principal Investigator: Alison K. Conlin
Phone: 773-702-9171
Click here to add this to my saved trials
Anchorage, Alaska 99504
Principal Investigator: Alison K. Conlin
Phone: 907-212-6871
Click here to add this to my saved trials
Anchorage, Alaska 98508
Principal Investigator: Alison K. Conlin
Phone: 907-212-6871
Click here to add this to my saved trials
Click here to add this to my saved trials
AnMedical Health Cancer Center Cancer is the general term for a group of more than...
Click here to add this to my saved trials
1500 East Medical Center Drive
Ann Arbor, Michigan 48109
Ann Arbor, Michigan 48109
800-865-1125
University of Michigan Comprehensive Cancer Center The U-M Comprehensive Cancer Center's mission is the conquest...
Click here to add this to my saved trials
5301 McAuley Drive
Ann Arbor, Michigan 48197
Ann Arbor, Michigan 48197
734-712-3456
Principal Investigator: Samir Narayan
Phone: 734-712-3671
Saint Joseph Mercy Hospital St. Joseph Mercy Ann Arbor Hospital is a 537-bed teaching hospital...
Click here to add this to my saved trials
Click here to add this to my saved trials
Antioch, California 94531
Principal Investigator: Samantha A. Seaward
Phone: 877-642-4691
Click here to add this to my saved trials
1506 South Oneida Street
Appleton, Wisconsin 54915
Appleton, Wisconsin 54915
Principal Investigator: Robert R. Kohl
Phone: 920-831-8900
Click here to add this to my saved trials
921 North Oak Park Boulevard
Arroyo Grande, California 93420
Arroyo Grande, California 93420
Principal Investigator: John A. Ellerton
Phone: 702-384-0013
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Asheville, North Carolina 28803
Principal Investigator: Raymond Thertulien
Phone: 828-650-8037
Click here to add this to my saved trials
Atlanta, Georgia 30322
Principal Investigator: Kristin A. Higgins
Phone: 404-778-1868
Click here to add this to my saved trials
550 Peachtree St NE
Atlanta, Georgia 30308
Atlanta, Georgia 30308
(404) 686-4411
Principal Investigator: Kristin A. Higgins
Phone: 888-946-7447
Emory University Hospital Midtown Emory University Hospital Midtown is a 511-bed community-based, acute care teaching...
Click here to add this to my saved trials
Atlanta, Georgia 30342
Principal Investigator: Kristin A. Higgins
Phone: 888-823-5923
Click here to add this to my saved trials
Click here to add this to my saved trials
Aurora, Colorado 80012
Principal Investigator: Keren Sturtz
Phone: 303-777-2663
Click here to add this to my saved trials
1501 S Potomac St
Aurora, Colorado 80012
Aurora, Colorado 80012
(303) 695-2600
Principal Investigator: Keren Sturtz
Phone: 303-777-2663
Medical Center of Aurora At The Medical Center of Aurora and Centennial Medical Plaza patients...
Click here to add this to my saved trials
12605 East 16th Avenue
Aurora, Colorado 80045
Aurora, Colorado 80045
720-848-0000
Principal Investigator: Brian D. Kavanagh
Phone: 720-848-0650
University of Colorado Hospital, Site Top medical professionals, superior medicine and progressive change make University...
Click here to add this to my saved trials
2000 Ogden Ave
Aurora, Illinois 60504
Aurora, Illinois 60504
(630) 978-6200
Principal Investigator: Sinisa Stanic
Phone: 630-978-6212
Rush - Copley Medical Center Rush-Copley is proud to be the leading provider of health...
Click here to add this to my saved trials
Aventura, Florida 33180
Principal Investigator: Michael A. Schwartz
Phone: 305-674-2625
Click here to add this to my saved trials
3325 Pocahontas Road
Baker City, Oregon 97814
Baker City, Oregon 97814
Principal Investigator: Benjamin T. Marchello
Phone: 734-712-3671
Click here to add this to my saved trials
Bakersfield, California 93301
Principal Investigator: David R. Gandara
Phone: 661-323-4673
Click here to add this to my saved trials
Baltimore, Maryland 21229
Principal Investigator: Richard S. Hudes
Phone: 410-368-2910
Click here to add this to my saved trials
2401 W Belvedere Ave
Baltimore, Maryland 21215
Baltimore, Maryland 21215
(410) 601-9000
Principal Investigator: Jeanette A. Linder
Phone: 410-601-6120
Sinai Hospital of Baltimore Sinai Hospital of Baltimore provides a broad array of high-quality, cost-effective...
Click here to add this to my saved trials
Greater Baltimore Medical Center The 255-bed medical center (acute and sub-acute care) is located on...
Click here to add this to my saved trials
22 South Greene Street
Baltimore, Maryland 21201
Baltimore, Maryland 21201
410-328-7904
Principal Investigator: Pranshu Mohindra
Phone: 800-888-8823
University of Maryland Greenebaum Cancer Center The University of Maryland Marlene and Stewart Greenebaum Cancer...
Click here to add this to my saved trials
Click here to add this to my saved trials
Summa Barberton Hospital Summa Barberton Hospital is a full member of Summa Health System and...
Click here to add this to my saved trials
Basking Ridge, New Jersey 07920
Principal Investigator: Andreas Rimner
Phone: 212-639-5007
Click here to add this to my saved trials
Baton Rouge, Louisiana 70806
Principal Investigator: William R. Robinson
Phone: 225-381-6451
Click here to add this to my saved trials
Baton Rouge, Louisiana 70809
Principal Investigator: David S. Hanson
Phone: 225-215-1353
Click here to add this to my saved trials
Click here to add this to my saved trials
Baton Rouge, Louisiana 70809
Principal Investigator: Augusto C. Ochoa
Phone: 225-215-1353
Click here to add this to my saved trials
Baton Rouge, Louisiana 70805
Principal Investigator: Augusto C. Ochoa
Phone: 504-568-2428
Click here to add this to my saved trials
4950 Essen Lane
Baton Rouge, Louisiana 70809
Baton Rouge, Louisiana 70809
Principal Investigator: Augusto C. Ochoa
Phone: 225-757-0343
Click here to add this to my saved trials
Beachwood, Ohio 44122
Principal Investigator: Min Yao
Phone: 800-641-2422
Click here to add this to my saved trials
Beaumont, Texas 77701
Principal Investigator: Ernest Hymel
Phone: 409-212-5956
Click here to add this to my saved trials
Beaver, Pennsylvania 15009
Principal Investigator: Liza C. Villaruz
Phone: 724-773-7616
Click here to add this to my saved trials
Click here to add this to my saved trials
Bellingham, Washington 98225
Principal Investigator: Alison K. Conlin
Phone: 360-715-4133
Click here to add this to my saved trials
800 Farson Street
Belpre, Ohio 45714
Belpre, Ohio 45714
(740) 401-0417
Principal Investigator: Timothy D. Moore
Phone: 800-523-3977
Strecker Cancer Center-Belpre The Memorial Health System's Strecker Cancer Center, Belpre combines the clinical expertise...
Click here to add this to my saved trials
Bemidji, Minnesota 56601
Principal Investigator: Preston D. Steen
Phone: 218-333-5000
Click here to add this to my saved trials
Bend, Oregon 97701
Principal Investigator: Alison K. Conlin
Phone: 541-706-2909
Click here to add this to my saved trials
Click here to add this to my saved trials
8901 Rockville Pike
Bethesda, Maryland 20889
Bethesda, Maryland 20889
(301) 295-4000
Principal Investigator: Stephen L. Lewis
Phone: 773-702-9171
Walter Reed National Military Medical Center The Walter Reed National Military Medical Center is one...
Click here to add this to my saved trials
Bettendorf, Iowa 52722
Principal Investigator: David M. Spector
Phone: 563-359-9876
Click here to add this to my saved trials
Click here to add this to my saved trials
Billings, Montana 59101
Principal Investigator: Benjamin T. Marchello
Phone: 800-996-2663
Click here to add this to my saved trials
1233 North 30th Street
Billings, Montana 59101
Billings, Montana 59101
406-237-7000
Principal Investigator: Keren Sturtz
Phone: 406-969-6060
Saint Vincent Healthcare The Sisters of Charity of Leavenworth, Kansas, founded St. Vincent Healthcare in...
Click here to add this to my saved trials
Birmingham, Alabama 35243
Principal Investigator: Michael C. Dobelbower
Phone: 205-934-0220
Click here to add this to my saved trials
Birmingham, Alabama 35233
Principal Investigator: Michael C. Dobelbower
Phone: 205-934-0220
Click here to add this to my saved trials
Mid Dakota Clinic, PC We're your family clinic, with the doctors you know and trust...
Click here to add this to my saved trials
Saint Alexius Medical Center St. Alexius Medical Center is a 306-bed, full-service, acute care medical...
Click here to add this to my saved trials
300 N. Seventh St.
Bismarck, North Dakota 58501
Bismarck, North Dakota 58501
(701) 323-6000
Principal Investigator: Preston D. Steen
Phone: 701-323-5760
Sanford Bismarck Medical Center Whether your stay in our hospital is one day for same...
Click here to add this to my saved trials
1505 Eastland Drive
Bloomington, Illinois 61701
Bloomington, Illinois 61701
309-662-2102
Principal Investigator: Bryan A. Faller
Phone: 309-243-3605
Illinois CancerCare-Bloomington Illinois CancerCare, P.C. is a comprehensive practice treating patients withcancer andblood diseases. Our...
Click here to add this to my saved trials
Bloomington, Illinois 61701
Principal Investigator: James L. Wade
Phone: 217-876-4740
Click here to add this to my saved trials
100 E Idaho St
Boise, Idaho 83712
Boise, Idaho 83712
(208) 381-2711
Principal Investigator: Alison K. Conlin
Phone: 773-702-9171
Saint Luke's Mountain States Tumor Institute For more than 100 years, St. Luke
Click here to add this to my saved trials
Boise, Idaho 83706
Principal Investigator: Benjamin T. Marchello
Phone: 734-712-3671
Click here to add this to my saved trials
Bonne Terre, Missouri 63628
Principal Investigator: Bryan A. Faller
Phone: 314-996-5569
Click here to add this to my saved trials
55 Fruit St
Boston, Massachusetts 02114
Boston, Massachusetts 02114
(617) 724-4000
Principal Investigator: David E. Kozono
Phone: 877-726-5130
Massachusetts General Hospital Cancer Center An integral part of one of the world
Click here to add this to my saved trials
450 Brookline Ave
Boston, Massachusetts 2215
Boston, Massachusetts 2215
617-632-3000
Principal Investigator: David E. Kozono
Phone: 877-442-3324
Dana-Farber Cancer Institute Since it’s founding in 1947, Dana-Farber has been committed to providing adults...
Click here to add this to my saved trials